Jiangsu Recbio Technology Co., Ltd.

Research Jiangsu Recbio Technology Co., Ltd. (G93) on Bullrun: market cap EUR 322.43M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerG93
• ExchangeF
• CountryChina
• SectorHealthcare
• IndustryBiotechnology
• CurrencyEUR
• Market capEUR 322.43M
• Financial periodFY2024
• Net income-EUR 562.39M
• Free cash flow-EUR 636.66M

Valuation Snapshot

latest market cap is EUR 322.43M.

About Jiangsu Recbio Technology Co., Ltd.

Jiangsu Recbio Technology Co., Ltd., a vaccine company, engages in the research, development, and commercialization of subunit vaccines in the People's Republic of China. The company develops vaccines for the treatment of cervical cancers, and anal and genital warts, including REC603, a recombinant human papillomavirus (HPV) 9-valent vaccine that is in phase III clinical trial; REC601, a recombinant HPV bivalent vaccines targeting HPV type 16/18 that is in phase I clinical trial;

Frequently asked questions

What is Jiangsu Recbio Technology Co., Ltd.'s market cap?

Jiangsu Recbio Technology Co., Ltd.'s market capitalization is EUR 322.43M.

What does Jiangsu Recbio Technology Co., Ltd. do?

Jiangsu Recbio Technology Co., Ltd., a vaccine company, engages in the research, development, and commercialization of subunit vaccines in the People's Republic of China.